Guildford, United Kingdom

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Investment Perspective

ANGLE’s updates reveal dialogue with FDA for Parsortix’s approval for use in mBC (metastatic breast cancer) is continuing and constructive, first submissions for accreditation of UK and US clinical laboratories have been made, but development of the ovarian cancer LDT (Laboratory Developed Test) has been hampered by a delay to data read out from a key study (due to third-party supply issues) to H122. A new study comparing CTC harvest and downstream analysis against biopsies in mBC shows good correlation and indicates Parsortix use could materially benefit clinical diagnoses and treatments. The longer wait for FDA approval and first LDT roll-out prompt us to revisit our forecasts and valuation models. Our new valuation of £506m ($658m), or 215p/share compares to £581m ($755m), 248p/share previously.

Market information

SymbolPrimary exchanges


£20m raise funds commercialisation through to mid-2024
Lighthouse | 15 Jul 2022
Parsortix FDA clearance marks a key transition point
Lighthouse | 26 May 2022
FY21 results: prepared for commercial success
Lighthouse | 28 Apr 2022

Recent News

Novel insights into metastasis in NSCLC
28 Jul 2022
Parsortix enables cancer DNA analysis in NSCLC
20 Jul 2022
Results of capital raise
15 Jul 2022
Proposed placing
14 Jul 2022